UKAS accreditation
Accreditation provides formal recognition that the Cellular Pathology Clinical Services Unit [CSU] at OUH is competent to perform Cytology, Histology and Post Mortem services [which are detailed in the scope of accreditation] in a reliable, credible and accurate manner.
The CSU undergoes inspection for conformance with internationally recognised standards of ISO15189:2022 [medical laboratory accrediation].
As an accredited service our users can have confidence in the quality of the results, their traceability, comparability, validity and commutability.
For more information on accreditation to ISO15189:2022, the process and benefits it brings, please visit:
For more general information please visit:
United Kingdom Accreditation Service (UKAS)
UKAS accredited tests
Cellular Pathology at the John Radcliffe and Nuffield Orthopaedic Centre sites have compliance with ISO15189:2012 reviewed annually.
The schedule of processes and tests that are currently accredited by UKAS can be found via the following links:
Cellular Pathology Service schedule of processes and tests (pdf) - UKAS
New / amended tests* undergo validation and quality assurance processes in order to be eligible for inclusion in the accredited schedule.
The validity of results are assessed though correlation with external sources; primarily this is through participation in national external quality assurance schemes (EQA).
If there is no relevant EQA scheme, the department ensures the results are accurate and valid by a combination of internal quality assurance tools and appropriate relevant external source such as:
- control material (known positives and negatives) with every run
- cross referencing to external images / information
- correlating results in panels
- comparing results with other laboratories
- requesting bespoke reviews by an EQA body
- double reporting or team reviews of results.
*This is approach is also used for research antibodies (i.e. not CE/IVD marked) which have been recommended for use by a professional body (such as the RCPath), NICE or within a peer reviewed paper.
'Non-accredited' tests
As a dynamic department, that continually seeks to improve for the benefit of patients, there are a number of tests and processes that are being developed or amended between accreditation visits.
This can arise due to:
- new tests becoming available
- recommendations for use by a professional body (such as the RCPath), NICE or within a peer reviewed paper
- service development projects.
Until they have been ratified by the UKAS team, it must be made clear that these new / amended tests / processes are not accredited by UKAS (see list in table below).
To ensure that tests are introduced in a safe way, with sound, scientific reasoning, the department follows prescribed procedures of acceptance testing, validation and verification of any new, or amended process.
| Test provided | Area of use | In-house validation status | Comment |
|---|---|---|---|
| BCoR | NOC | Complete | UKAS approval required |
| CD56 | NOC | Complete | UKAS approval required |
| CD79a | NOC | Complete | UKAS approval required |
| CK5/6 | NOC | Complete | UKAS approval required |
| ERG | NOC | Complete | UKAS approval required |
| H3.3 G34W | NOC | Complete | UKAS approval required |
| H3K36M | NOC | In progress | UKAS approval required |
| MITF | NOC | Complete | UKAS approval required |
| PanTRK | NOC | Complete | UKAS approval required |
| Retinoblastoma | NOC | Complete | UKAS approval required |
| SMA | NOC | Complete | UKAS approval required |
| Von Kossa | NOC | Complete | UKAS approval required |
| BRAF V600E | JR | Complete | UKAS approval required |
| STAT6 | JR | Complete | UKAS approval required |
| ERG | JR | Complete | UKAS approval required |
| INI-1 | JR | Complete | UKAS approval required |
| NELL | JR | Complete | UKAS approval required |
| NUT-1 | JR | Complete | UKAS approval required |
| Parathyroid Hormone (PTH) | JR | Complete | UKAS approval required |
| PRAME | JR | Complete | UKAS approval required |
| CD163 | NOC | Complete | UKAS approval required |
| DDIT3 | NOC | Complete | UKAS approval required |
| MyoD1 | NOC | Complete | UKAS approval required |
| NKX3.1 | NOC | Complete | UKAS approval required |
| PAX8 | NOC | Complete | UKAS approval required |
| SOX10 | NOC | Complete | UKAS approval required |
| SS18-SSX (SYT) | NOC | Complete | UKAS approval required |
| Alkaline Phosphatase | NOC | Complete | UKAS approval required |
| Masson Fontana | NOC | Complete | UKAS approval required |
For tests which the department is unable to follow the normal validation steps (see above), the continued use of a test will be clearly identified to relevant service users.

